That's fine and dandy, but think too many got comfortable with this notion that Iclusig would just sweep up 1L and 2L, despite head-to-head data. Safety matters greatly to patients and community oncologists.
I do get the feeling Harvey is rushing it a bit. As biomaven said, they probably could use a little more work on dosing strategies if they want front-line and second-line.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.